New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
November 04 2019 - 8:00AM
Business Wire
-- Data to be presented from in-practice
clinician case series on novel immunomodulation strategy --
Horizon Therapeutics plc (Nasdaq: HZNP) today announced multiple
presentations that will highlight the serious, systemic effect of
urate deposition and will inform strategies to optimize treatment
of uncontrolled gout through immunomodulation during the American
College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in
Atlanta.
Presentation details:
- Subcutaneous or Oral Methotrexate Exposure and Response to
Pegloticase In Uncontrolled Gout Patients in a Community
Rheumatology Practice
- Abstract: 1236, J. Albert
- Monday, Nov. 11, 2019; 9 – 11 a.m. ET
- Improvement in Hepatic Fibrosis Estimated by Fibrosis-4
(FIB-4) Index in Subjects with Chronic Refractory Gout Treated with
Pegloticase
- Abstract: 1231, N. Schlesinger
- Monday, Nov. 11, 2019; 9– 11 a.m. ET
- Renal Transplant Complications in Patients with and without
Gout
- Abstract: 335, M. Francis-Sedlak
- Sunday, Nov. 10, 2019; 9 – 11 a.m. ET
In addition, Horizon will host a presentation featuring Ada J.
Kumar, M.D., Horizon associate medical director, on Monday, Nov. 11
at 3:30 p.m. ET in Innovation Theater B, to illustrate the breadth
of uric acid crystal’s impact beyond the joints, to multiple other
tissues, through historical and advanced imagery.
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com, follow us @HorizonNews on
Twitter, like us on Facebook or explore career opportunities on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191104005150/en/
Contacts: Tina Ventura Senior Vice President,
Investor Relations Investor-relations@horizontherapeutics.com
Ruth Venning Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com
U.S. Media Contacts: Amanda Phraner Associate
Director, Public Relations and Social Media
media@horizontherapeutics.com
Ireland Media Contact: Gordon MRM Ray Gordon
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Sep 2023 to Sep 2024